Zydus Lifesciences Trade 1% Lower on USFDA Approval
Shares of Zydus Lifesciences Ltd were trading in the red and 1% lower on 2 June after they announced securing tentative approval from the US Food and Drug Administration (USFDA) for Rifaximin tablets, 550 mg. Zydus Life stated that the tablets are approved for the treatment of irritable bowel syndrome with diarrhoea in adults. The…